LivaNova (NASDAQ:LIVN) and Nexeon Medsystems (OTCMKTS:NXNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Valuation & Earnings
This table compares LivaNova and Nexeon Medsystems’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|LivaNova||$1.08 billion||1.90||-$155.18 million||$3.08||13.84|
|Nexeon Medsystems||$3.30 million||0.62||-$2.17 million||N/A||N/A|
Nexeon Medsystems has lower revenue, but higher earnings than LivaNova.
Insider and Institutional Ownership
91.5% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 61.2% of Nexeon Medsystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
LivaNova has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Nexeon Medsystems has a beta of 3.29, indicating that its stock price is 229% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for LivaNova and Nexeon Medsystems, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LivaNova currently has a consensus target price of $83.83, indicating a potential upside of 96.65%. Given LivaNova’s higher possible upside, analysts clearly believe LivaNova is more favorable than Nexeon Medsystems.
This table compares LivaNova and Nexeon Medsystems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
LivaNova beats Nexeon Medsystems on 7 of the 11 factors compared between the two stocks.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Nexeon Medsystems Company Profile
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.